跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
KADCYLA 160 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
KADCYLA 160 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION
Approved
STANDARD
KADCYLA 160 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION
Roche Registration Gmbh
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Nov 2, 2020
Approval ID
33360790bfba7e80
Company
Roche Registration Gmbh
Type
Standard
Approval Details
Approval Id
33360790bfba7e80
Drug Cima Aemps Name
KADCYLA 160 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION
Register Number
113885002IP
Holder Company Name
Roche Registration Gmbh
Marketing Company Name
Abacus Medicine A/S
Holder Company Detail Path
/organization/roche-registration-gmbh
Authorization Date
2020-11-02
Dosage Form
POLVO PARA CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓN
Dose
160 mg
Route Of Administration
VÍA INTRAVENOSA
Prescription Type
Uso Hospitalario
Commercialized
Yes
Company Name
Roche Registration Gmbh
Company Detail Path
/organization/roche-registration-gmbh
Company Information
Pharmaceutical Company Name
Roche Registration GmbH
Country Name
Germany
City Name
grenzach-wyhlen,baden-württemberg,country_de
Address
Emil-Barell-Str. 1
Active Ingredients
TRASTUZUMAB EMTANSINA
20 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Nov 2, 2020
Approval ID
33360790bfba7e80
Type
Standard
Back to CIMA-AEMPS Approvals